Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity, Inc. reporting persons filed an amendment to their Schedule 13G/A disclosing beneficial ownership stakes in the company's capital structure.
The filing shows that Jeffrey Tangney and Claudia Schweikert (and related trusts) collectively beneficially own large positions: Tangney and Schweikert each report 55,459,800 shares (treated as 29.9% of Class A on a conversion basis). The filing states the conversion and voting mechanics for Class B shares and provides outstanding share counts as of March 31, 2026.
Doximity, Inc. interim PFO and PAO Siddharth Sitaram reported routine equity transactions involving Class A and Class B shares. He exercised a stock option covering 5,000 shares of Class B Common Stock at a $4.12 exercise price, which converted into 5,000 shares of Class A Common Stock. On the same date, he sold 2,309 shares of Class A Common Stock at $25.77 per share in an automatic Rule 10b5-1 sell-to-cover transaction to satisfy tax withholding obligations. Following these transactions, he directly held 91,705 shares of Class A Common Stock.
Doximity, Inc. interim PFO and PAO Siddharth Sitaram reported routine equity transactions involving Class A and Class B shares. He exercised a stock option covering 5,000 shares of Class B Common Stock at a $4.12 exercise price, which converted into 5,000 shares of Class A Common Stock. On the same date, he sold 2,309 shares of Class A Common Stock at $25.77 per share in an automatic Rule 10b5-1 sell-to-cover transaction to satisfy tax withholding obligations. Following these transactions, he directly held 91,705 shares of Class A Common Stock.
Doximity, Inc. reported fiscal year 2026 revenue of $644.9 million, up 13% from $570.4 million, with adjusted EBITDA rising to $357.8 million and free cash flow to $317.5 million, both up 14–19% year-over-year.
GAAP net income for the year declined to $196.1 million from $223.2 million as margins narrowed, though non-GAAP net income improved to $302.7 million. In Q4, revenue grew 5% to $145.4 million, while net income fell to $19.1 million, reflecting higher operating expenses and stock-based compensation. The company highlighted strong engagement, with over 800,000 active prescribers using workflow tools in Q4 and broad adoption of its clinical AI features.
For fiscal 2027, Doximity guides to revenue of $664–$676 million and adjusted EBITDA of $323–$335 million. The company also appointed Matthew Sonefeldt as Chief Financial Officer and Steven L. Zatz, M.D. as President, each with base salary of $400,000 and multi‑year RSU packages tied to time-based and performance-based vesting.
Doximity, Inc. reported fiscal year 2026 revenue of $644.9 million, up 13% from $570.4 million, with adjusted EBITDA rising to $357.8 million and free cash flow to $317.5 million, both up 14–19% year-over-year.
GAAP net income for the year declined to $196.1 million from $223.2 million as margins narrowed, though non-GAAP net income improved to $302.7 million. In Q4, revenue grew 5% to $145.4 million, while net income fell to $19.1 million, reflecting higher operating expenses and stock-based compensation. The company highlighted strong engagement, with over 800,000 active prescribers using workflow tools in Q4 and broad adoption of its clinical AI features.
For fiscal 2027, Doximity guides to revenue of $664–$676 million and adjusted EBITDA of $323–$335 million. The company also appointed Matthew Sonefeldt as Chief Financial Officer and Steven L. Zatz, M.D. as President, each with base salary of $400,000 and multi‑year RSU packages tied to time-based and performance-based vesting.
Reporting person Siddharth submitted a notice of proposed sale of 2,309 shares of Common Stock of DOCS by means described as a Stock Option Exercise to be effected on 05/11/2026. The filing also lists prior sales of 2,427 shares on 04/10/2026 and 2,319 shares on 03/10/2026.
Doximity, Inc. director Kira Scherer Wampler reported an open-market sale and related equity conversions. On May 7, 2026, she sold 9,000 shares of Class A Common Stock at $26.06 per share and held 19,839 Class A shares afterward.
On the same date, she exercised and converted derivative positions involving 9,000 shares of Class B Common Stock into Class A Common Stock and partially exercised a stock option covering 9,000 underlying Class B shares at a $1.54 exercise price. A footnote states the sale occurred automatically under a Rule 10b5-1 trading plan adopted on November 12, 2024, indicating the transaction was pre‑planned rather than discretionary.
DOCS filed a Form 144 disclosing an intended sale of 9,000 shares of Common stock via a Stock Option Exercise on 05/07/2026 for cash. The filing records a prior sale of 2,000 shares by Kira Wampler on 03/03/2026 for $52,000.
Doximity Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 6,785,531 shares of common stock, representing 5.07% of the class as reported in the Schedule 13G. The filing shows sole dispositive power over 6,785,531 shares and sole voting power over 1,020,468 shares. The report notes these holdings reflect securities held for Vanguard funds and managed accounts and attributes voting/dispositive powers across Vanguard affiliates.
Doximity, Inc. announced that Chief Financial Officer Anna Bryson, who had been on medical leave since early February 2026, resigned from her role effective April 13, 2026. Chief Accounting Officer Siddharth Sitaram continues to serve as interim principal financial and accounting officer until a new CFO is appointed.
The company plans to give an update on its CFO search during its next earnings call. Doximity also reaffirmed its previously issued guidance for the fourth quarter and full fiscal year ending March 31, 2026, as first shared on February 5, 2026.
Doximity interim PFO and PAO Siddharth Sitaram exercised and converted derivative awards and sold a portion of shares in connection with taxes. On April 10, 2026, he exercised a stock option for 5,000 shares at $4.12 per share and converted 5,000 Class B into 5,000 Class A shares.
He then sold 2,427 Class A Common Stock at $21.09 per share in a sell-to-cover transaction to satisfy tax withholding obligations under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly held 86,705 shares of Class A Common Stock and 78,800 option shares.
The filing reports proposed sales of Common stock under a Form 144 by an affiliate, with a trade date of 04/10/2026 tied to a stock option exercise handled by Morgan Stanley Smith Barney LLC. The excerpt lists three completed dispositions in the prior three months (2324, 2319, 2282 shares) with associated cash amounts and an indicated sale method of Cash.